Expanding treatment options in ulcerative colitis CP 1

with Professor Séverine Vermeire from UZ Leuven - Accreditation: 19060167

__FILL_ME_OUT__
Lesduur: 60min
Gepubliceerd:
Accreditatie tot:

Om deze les te volgen dient u een account te hebben en moet u zich aanmelden.

Geen account? Registreer u hier.

A new treatment option is now available for moderately to severely active Ulcerative Colitis (UC). This new drug tofacitinib is the 1st & only JAK inhibitor registered for UC. Tofacitinib is an oral small molecule, targeting inflammation from inside the cell. This introduction marks a new era in the treatment of UC. The efficacy and safety of tofacitinib has been established in an extensive clinical trial program, and the emerging Real World data confirms this profile to date. The two available doses and the short half-life allow for a practical treatment flexibility of your UC patients.

Learn more about tofacitinib with Professor Séverine Vermeire from UZ Leuven, who has extensive clinical trial and real-world experience with this innovative new treatment in UC.